Kimberly-Clark Corporation (KMB) Stock Price & How to Invest

Kimberly-Clark is a consumer staples company that makes and sells personal care and tissue products under household brand names. Its portfolio includes Huggies diapers, Pull-Ups training pants, Kotex feminine care, Depend and Poise adult incontinence products, Kleenex tissues, Cottonelle and Scott bath tissue, and Viva paper towels. The company organizes around Personal Care (its largest and most profitable business), Consumer Tissue, and a professional/away-from-home business serving offices, restaurants, and institutions (sold under the Kimberly-Clark Professional banner). Roughly half of revenue comes from outside North America, with meaningful exposure to developing and emerging markets where category penetration is still rising. Kimberly-Clark makes money by selling repeat-purchase, non-discretionary household essentials at scale, leaning on brand strength, retail distribution, and manufacturing efficiency. The business is a classic defensive staple: steady demand, modest organic growth, and a long dividend history. Headquartered in Irving, Texas, it has been a Dividend Aristocrat for decades.

The company is in the middle of a large reshaping. Reported revenue fell from about $20 billion in 2024 to about $16.5 billion in 2025 as the international tissue business it is moving into a joint venture was taken out of continuing operations, and trailing twelve-month revenue was about $16.6 billion as of mid-2026. Kimberly-Clark is also nearing completion of its acquisition of Kenvue, a deal reported at roughly $40 billion, backed by $7.7 billion of bridge financing from JPMorgan and expected to close by the end of 2026; in mid-October 2026 it held investor calls ahead of a possible five-part bond sale. Preliminary third-quarter 2026 figures released October 15 showed net sales of about $4.13 billion and adjusted EPS of $1.70, both ahead of consensus, though China sales were hurt by disruptions tied to social-media activity there. As of October 16, 2026 the stock was up about 4% year to date and down about 12% over one year.

Kimberly-Clark sells largely commoditized products where private-label store brands compete aggressively on price, capping pricing power and pressuring volumes when consumers trade down. Input costs (pulp, resin, energy) and currency swings hit margins directly given heavy emerging-market exposure, and China has become a specific drag after the 2026 social-media backlash. Organic growth is structurally slow, so the stock behaves like a bond proxy and can lag in risk-on markets and underperform when interest rates rise. The Kenvue deal adds integration risk and new borrowing on a balance sheet that already carries about $6.5 billion of debt against under $1 billion of cash, and trailing free cash flow of about $0.9 billion is well below the roughly $2 billion of earlier years. Major customers like Walmart hold negotiating leverage, and birth-rate declines in developed markets pressure the diaper category over time. UBS cut its price target to $106 from $116 in October 2026.

15 analysts publish price targets on KMB, averaging $114.20 against a $105.57 price as of October 2026, or +8.2%. The published targets run from $90.00 to $162.00, a moderate spread, and the ratings split 7 buy, 8 hold, 1 sell. Over the last six months there have been 7 raises and 5 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full KMB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Kimberly-Clark Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Defensive, repeat-purchase demand. Diapers, tissue, and feminine and incontinence care are non-discretionary essentials bought regardless of the economic cycle. The most optimistic published target, $162.00, assumes this works close to its best case.

The case against. Kimberly-Clark sells largely commoditized products where private-label store brands compete aggressively on price, capping pricing power and pressuring volumes when consumers trade down. The most pessimistic target, $90.00, is roughly what KMB is worth if this bites instead.

Read the full bull and bear case on KMB, including what would have to change to break either one. Walnut is not an investment adviser.

No. Kimberly-Clark Corporation (KMB) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Kimberly-Clark Corporation's investor relations page or your broker.

• Revenue (TTM, continuing operations): ~$16.6 billion (flat YoY)
• Operating margin: ~19%
• Net income (TTM): ~$1.7 billion (EPS ~$5.07)
• P/E: ~21x trailing, ~14x forward
• Dividend yield: ~4.9% (~$5.12/yr)
• Dividend growth streak: 50+ consecutive years (Dividend Aristocrat)
• Market cap: ~$35 billion
• Free cash flow (TTM): ~$0.9 billion

Kimberly-Clark trades at about 14 times forward earnings, a discount to its own history after a roughly 12% decline over the past year, and the dividend yield has climbed to about 4.9%. The trailing P/E near 21 is inflated by one-time items in GAAP earnings tied to its restructuring. The multiple remains sensitive to interest rates, and for the next few quarters also to how the market judges the Kenvue acquisition and its financing.

If you want KMB exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses KMB naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to KMB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get KMB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (DVY), which spreads the position across many companies. Or build it into a focused thematic portfolio, so KMB sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where KMB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Kimberly-Clark (KMB) is a slow-growth, bond-proxy staple whose recurring demand for diapers, tissue, and personal care funds a 50-plus-year dividend-growth streak, now yielding about 4.9% at a share price near $105 (October 16, 2026). In a portfolio it behaves as a low-volatility income and stability anchor, sensitive to interest rates, pulp and resin costs, and private-label competition rather than to the economic cycle, with the pending Kenvue deal adding integration and leverage risk on top.

Whether KMB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is KMB a buy or a sell?, and where the stock could go from here in the KMB stock forecast.

For income investors, whether KMB pays a dividend and how the payout looks is covered in does KMB pay a dividend? And to weigh KMB against a peer, read the full side-by-side comparisons: KMB vs ABT and KMB vs CL.